LOG IN
SIGN UP
MARKET
AIM
AIM
Aim Immunotech
AMEX
Real-time Quotes | Nasdaq Last Sale
0.9300
+0.0100
+1.09%
Closed 16:00 05/27 EDT
OPEN
0.9200
PREV CLOSE
0.9200
HIGH
0.9400
LOW
0.9001
VOLUME
87.64K
TURNOVER
44.91K
52 WEEK HIGH
2.400
52 WEEK LOW
0.5500
MARKET CAP
44.69M
P/E (TTM)
-2.3111
1D
5D
1M
3M
1Y
5Y
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira...
GlobeNewswire · 05/19 12:00
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares rose 20.9% to $0.70 in pre-market trading after dropping 12% on Wednesday. Acorda Therapeutics recently posted a Q1 loss of $1.66 per share.
Benzinga · 05/19 10:44
AIM working on new drug application for Ampligen mid-stage study to treat long COVID
AIM ImmunoTech (NYSE:AIM) on Wednesday said it was working toward filing an investigational new drug application with the U.S. Food and Drug Administration for a phase 2 study of its
Seekingalpha · 05/18 13:27
BRIEF-AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
reuters.com · 05/18 12:43
BRIEF-AIM Immunotech Reports Q1 Loss From Operations Of $3.8 Mln
reuters.com · 05/16 11:48
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira...
GlobeNewswire · 05/12 12:05
A Preview Of AIM ImmunoTech's Earnings
AIM ImmunoTech (AMEX:AIM) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that AIM ImmunoTech will report an earnings per share (EPS) of $-0.07.
Benzinga · 05/05 17:13
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday.
Benzinga · 04/26 10:00
No Data
Learn about the latest financial forecast of AIM. Analyze the recent business situations of Aim Immunotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AIM stock price target is 5.83 with a high estimate of 8.00 and a low estimate of 3.000.
Current 0.9300
EPS
Actual
Estimate
-0.10-0.07-0.05-0.02
Institutional Holdings
Institutions: 15
Institutional Holdings: 93.54K
% Owned: 0.19%
Shares Outstanding: 48.05M
TypeInstitutionsShares
Increased
6
31
New
4
70.90K
Decreased
2
2.90K
Sold Out
7
13.03K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/Executive Director
Thomas Equels
Chief Financial Officer
Robert Dickey
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Chief Scientific Officer
David Strayer
Independent Director
Stewart Appelrouth
No Data
No Data
About AIM
AIM ImmunoTech Inc. is a specialty pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The Company's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.
Webull offers kinds of AIM ImmunoTech Inc stock information, including AMEX:AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.